Recent Progress in Dendritic Cell-Based Cancer Immunotherapy
Cancer immunotherapy aims to treat cancer by enhancing cancer-specific host immune responses. Recently, cancer immunotherapy has been attracting much attention because of the successful clinical application of immune checkpoint inhibitors targeting the CTLA-4 and PD-1/PD-L1 pathways. However, althou...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/10/2495 |
| _version_ | 1797533338377912320 |
|---|---|
| author | Kazuhiko Matsuo Osamu Yoshie Kosuke Kitahata Momo Kamei Yuta Hara Takashi Nakayama |
| author_facet | Kazuhiko Matsuo Osamu Yoshie Kosuke Kitahata Momo Kamei Yuta Hara Takashi Nakayama |
| author_sort | Kazuhiko Matsuo |
| collection | DOAJ |
| description | Cancer immunotherapy aims to treat cancer by enhancing cancer-specific host immune responses. Recently, cancer immunotherapy has been attracting much attention because of the successful clinical application of immune checkpoint inhibitors targeting the CTLA-4 and PD-1/PD-L1 pathways. However, although highly effective in some patients, immune checkpoint inhibitors are beneficial only in a limited fraction of patients, possibly because of the lack of enough cancer-specific immune cells, especially CD8<sup>+</sup> cytotoxic T-lymphocytes (CTLs), in the host. On the other hand, studies on cancer vaccines, especially DC-based ones, have made significant progress in recent years. In particular, the identification and characterization of cross-presenting DCs have greatly advanced the strategy for the development of effective DC-based vaccines. In this review, we first summarize the surface markers and functional properties of the five major DC subsets. We then describe new approaches to induce antigen-specific CTLs by targeted delivery of antigens to cross-presenting DCs. In this context, the chemokine receptor XCR1 and its ligand XCL1, being selectively expressed by cross-presenting DCs and mainly produced by activated CD8<sup>+</sup> T cells, respectively, provide highly promising molecular tools for this purpose. In the near future, CTL-inducing DC-based cancer vaccines may provide a new breakthrough in cancer immunotherapy alone or in combination with immune checkpoint inhibitors. |
| first_indexed | 2024-03-10T11:14:05Z |
| format | Article |
| id | doaj.art-4c9f19946d2c4162b2e17fee777d2464 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:14:05Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4c9f19946d2c4162b2e17fee777d24642023-11-21T20:34:04ZengMDPI AGCancers2072-66942021-05-011310249510.3390/cancers13102495Recent Progress in Dendritic Cell-Based Cancer ImmunotherapyKazuhiko Matsuo0Osamu Yoshie1Kosuke Kitahata2Momo Kamei3Yuta Hara4Takashi Nakayama5Division of Chemotherapy, Kindai University Faculty of Pharmacy, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, JapanKindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, JapanDivision of Chemotherapy, Kindai University Faculty of Pharmacy, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, JapanDivision of Chemotherapy, Kindai University Faculty of Pharmacy, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, JapanDivision of Chemotherapy, Kindai University Faculty of Pharmacy, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, JapanDivision of Chemotherapy, Kindai University Faculty of Pharmacy, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, JapanCancer immunotherapy aims to treat cancer by enhancing cancer-specific host immune responses. Recently, cancer immunotherapy has been attracting much attention because of the successful clinical application of immune checkpoint inhibitors targeting the CTLA-4 and PD-1/PD-L1 pathways. However, although highly effective in some patients, immune checkpoint inhibitors are beneficial only in a limited fraction of patients, possibly because of the lack of enough cancer-specific immune cells, especially CD8<sup>+</sup> cytotoxic T-lymphocytes (CTLs), in the host. On the other hand, studies on cancer vaccines, especially DC-based ones, have made significant progress in recent years. In particular, the identification and characterization of cross-presenting DCs have greatly advanced the strategy for the development of effective DC-based vaccines. In this review, we first summarize the surface markers and functional properties of the five major DC subsets. We then describe new approaches to induce antigen-specific CTLs by targeted delivery of antigens to cross-presenting DCs. In this context, the chemokine receptor XCR1 and its ligand XCL1, being selectively expressed by cross-presenting DCs and mainly produced by activated CD8<sup>+</sup> T cells, respectively, provide highly promising molecular tools for this purpose. In the near future, CTL-inducing DC-based cancer vaccines may provide a new breakthrough in cancer immunotherapy alone or in combination with immune checkpoint inhibitors.https://www.mdpi.com/2072-6694/13/10/2495cancer vaccineadjuvantdendritic cellschemokineXCR1XCL1 |
| spellingShingle | Kazuhiko Matsuo Osamu Yoshie Kosuke Kitahata Momo Kamei Yuta Hara Takashi Nakayama Recent Progress in Dendritic Cell-Based Cancer Immunotherapy Cancers cancer vaccine adjuvant dendritic cells chemokine XCR1 XCL1 |
| title | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy |
| title_full | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy |
| title_fullStr | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy |
| title_full_unstemmed | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy |
| title_short | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy |
| title_sort | recent progress in dendritic cell based cancer immunotherapy |
| topic | cancer vaccine adjuvant dendritic cells chemokine XCR1 XCL1 |
| url | https://www.mdpi.com/2072-6694/13/10/2495 |
| work_keys_str_mv | AT kazuhikomatsuo recentprogressindendriticcellbasedcancerimmunotherapy AT osamuyoshie recentprogressindendriticcellbasedcancerimmunotherapy AT kosukekitahata recentprogressindendriticcellbasedcancerimmunotherapy AT momokamei recentprogressindendriticcellbasedcancerimmunotherapy AT yutahara recentprogressindendriticcellbasedcancerimmunotherapy AT takashinakayama recentprogressindendriticcellbasedcancerimmunotherapy |